Ken Fisher & Jim Simons: Two Billionaires Bulking Up On Drugs

Page 1 of 2

FISHER ASSET MANAGEMENTBillionaires Ken Fisher and Jim Simons are two of the top names in the money management business. Fisher runs Fisher Asset Management and is also a long-time columnist for Forbes. Fisher founded Fisher Asset Management in 1979 and has been writing for Forbes for over 25 years. Here’s Ken Fisher’s full equity portfolio.

Simons founded Renaissance Technologies (RenTech) in 1982 and the firm continues to manage various hedge funds across the world. Simons’ Medallion Fund is one of the best in the industry, making Simons a very rich man while using high frequency trading to exploit inefficiencies in the stock market. Simons stepped down as CEO of RenTech in 2010 and the fund’s investors are now mainly current and past employees (check out Jim Simons’ latest picks).

In reviewing the duo’s latest 13F filings with the SEC – which reveal most of the publicly traded securities that each manager owns – we found that Fisher and Simons both have big bets in the pharma industry. Fisher and Simons each have two pharma stocks in their top five holdings, and have almost $3 billion invested cumulatively across five big-name pharma companies.

Our first pharma company is Fisher’s number one stock holding in his 13F, Pfizer Inc. (NYSE:PFE). Fisher increased his stake in Pfizer by 45% last quarter after the pharma stock traded relatively flat in 2Q. Pfizer completed the sale of its nutrition business to Nestle for $11 billion, which puts it on its path for realignment. Spurring Pfizer on will be its plan to IPO some 20% of its animal health business, with proceeds used to drive further dividend increases and its $10 billion share repurchase program that was recently announced.

Johnson & Johnson (NYSE:JNJ) is another one of Fisher’s big time bets, being the second largest stock holding in his 3Q 13F. Revenues are expected to be up 8% in 2013 thanks in part to a full year of Synthes’ integrated sales. The Synthes acquisition will help Johnson & Johnson expand its product offering to more orthopedic products, and is expected to add $4 billion in sales in 2013. Fellow billionaire investor George Soros also has Johnson & Johnson as one of his latest bets, increasing his stake by over 1500% during the third quarter (check out George Soros’ new picks).

GlaxoSmithKline PLC (NYSE:GSK) is another one of Fisher’s pharma bets and is the 23rd largest holding in his 13F portfolio. Fisher increased his stake by 130% last quarter. Revenues for Glaxo are expected to be flat for 2012 as the pharma company sees erosion in older drug lines. Volume gains in new pharmaceuticals, such as Lovaza, should help counter this erosion in the interim, and is expected to drive sales growth in the mid-single digits for 2013. Glaxo will likely see the most pressure of our five pharma stocks given its above-average exposure to Europe.

Page 1 of 2
blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months Click to see monthly returns in table format!

Lists

The 10 Most Overrated Movies Of All Time by Out-of-Touch Critics

Top 6 Least Expensive Cruise Destinations For 2015 that Will Take You to Paradise

10 States with Lowest Substance Abuse Rates in America

The 14 Most Watched TV Finales Ever

The 10 Best Selling Role Playing Games of All Time for PC

10 Most Influential Papers In Economics

Top 8 Biggest Charities in the US

10 Worst Celebrity Career Moves Ever

Top 10 Best Paid Tennis Stars in the World

10 Cities with High Demand for Nurses

6 of the Worst Greeting Card Messages Ever Crafted

6 Ways to Make Money in ArcheAge and Build Your Empire

10 Foods To Eat To Lower Cholesterol Levels

The 10 Most Hated Television Characters of All Time

The 30 Worst Halloween Costume Ideas Ever Brought to Horrible Life

10 Vocational Skills in Demand Today with Jobs Waiting to be Filled

10 Best Places to Visit in Central and South America

The 10 Greatest Empires in History Which Nearly Conquered the World

The 6 Cheapest Boarding Schools In America 2015

5 Clear Reasons LoL is Better than DotA, Continues to Rule MOBAs

The Only 9 Teams with a Chance to Win the Super Bowl

The 15 Most Common Phobias in America that Induce Fits of Panic

Top 6 Least Expensive Tourist Destinations in 2014

Jim Goetz, Peter Fenton, Jim Breyer: Top 6 Venture Investors for 2014

Top 15 Billionaires in 2014

5 Pitfalls To Avoid When Buying a Franchise

Top 20 Medical Schools in the US – 2014 Rankings

4 Business Strategies that Turned Jamie Oliver into the World’s Richest Chef

6 Qualities That Make You A Good Team Player

10 High Paying Seasonal Jobs in America this Holiday Season

The 10 Busiest Shipping Lanes in the World

5 Most Valuable Brands in China

The 10 States with Highest Substance Abuse Rates Crippling Their Populace

The Top 10 Things to Do Before You Die That Will Echo for Eternity

The 10 Best Selling Items on Etsy

Top 10 Things to Do in Tokyo, the Greatest City in the World

10 Mistakes on Social Media that Can Harm You and Will Probably Get You Canned

The 10 Best Cities to Find Jobs in 2014

The 10 Most Controversial Songs Of All Time to Hit (and get Banned from) the Airwaves

The 20 Biggest IPOs in US History

The 10 Best Places to Visit in Mexico that Are Beautiful and Safe

7 Bad Habits that Age You Beyond Your Years

The 40 Best Fortune Cookie Sayings That Will Leave You Bemused, Befuddled, or Beguiled

10 Foods to Eat Before a Workout to Make Every Drop of Sweat Count

The 5 Best Documentaries On Netflix You Must See

The Most Heartwarming and Inspirational Story Of This Halloween Season, It Will Make You Cry and Jump For Joy

10 Best Party Songs of All Time to Bring the House Down With

5 New World Order Conspiracy Theories that Will Strangle the World

The 10 Highest Rated Movies of 2014

The 10 Largest Container Shipping Companies in the World

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!